Primary CNS Lymphoma (PCNSL) Market View Report 2026: Pipeline Holds 43 Molecules, with No Assets in the Pre-registration Stage, One Asset in Phase III Development, and Another 23 in Phase II

Wednesday, May 6, 2026 · research and markets

AI Briefing

Urban China expected to lead globally in diagnosed PCNSL cases in 2024 and 2029.
Significant unmet need driving development of new therapies.
Robust pipeline activity and strategic partnerships highlight key market opportunities.